Bacteria building resistance to moxifloxacin

Article

Although moxifloxacin has excellent antibacterial coverage, there is an emergence of a resistance to it in bacteria isolated from corneal ulcers.

Although moxifloxacin has excellent antibacterial coverage, there is an emergence of a resistance to it in bacteria isolated from corneal ulcers, according to Gita Sathpathy and co-workers at the All India Institute of Medical Sciences, New Dehli, India.

The records of 934 consecutive cases of bacterial corneal ulcers were retrospectively reviewed and culture and antibiotic sensitivity reports of corneal scrapings were analysed. Recorded parameters included age, sex, organism isolated and sensitivity, using Kirby-Bauer disc-diffusion, to moxifloxacin. The bacterial isolates that were resistant to moxifloxacin were examined in detail and their antibiotic sensitivity to other drugs was studied.

Of the 934 bacterial isolates, 913 (97.5%) were sensitive to moxifloxacin and 21 (2.25%) were found to be resistant. Of the 21 resistant isolates, eight were Staphylococcus albus, eight were Pseudomonas, two were Streptococcus viridians, one was Streptococcus pneumoniae, one was Staphylococcus aureus and one was E. coli. Of the eight Pseudomonas cases, six were found to be sensitive to polymyxin and five sensitive to amikacin. Out of the eight Staphylococcus, seven were sensitive to vancomycin.

The emergence of a resistance to moxifloxacin in bacteria isolated from corneal ulcers, indicates that the drug should not be used indiscriminately.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.